AIxCrypto Holdings Launches Agentir to Transform AI and Blockchain Integration
- AIxCrypto Holdings launched "Agentir" to enhance AI Agents' performance evaluation, bridging Web2 and Web3 technologies.
- The company reports 4.8 million wallet addresses, indicating strong user engagement with AI-driven solutions and products.
- AIxCrypto promotes community-driven innovation and modular development, democratizing access to AI technology for all users.
AIxCrypto Holdings Enhances AI Ecosystem with Agentir Launch
AIxCrypto Inc. (NASDAQ: AIXC), a company at the forefront of integrating artificial intelligence and blockchain technologies, unveils a pivotal advancement in its ecosystem with the introduction of "Agentir." This new environment is dedicated to the performance evaluation of AI Agents, reflecting AIxCrypto's commitment to foster growth in the convergence of Web2 and Web3. As of February 2026, the company reports a staggering 4.8 million registered wallet addresses, among which 3.7 million have utility points accumulated, showcasing heightened engagement with its platform. These figures reveal the burgeoning interest from users in AI-driven solutions as the company simplifies the creation of AI products through modular building blocks and natural-language tools.
The momentum behind AIxCrypto is underscored by its rapid user adoption, as evidenced by the 336% increase in registered wallet addresses within just one month. Such growth not only signifies a strong demand for AI agent applications but also illustrates the effectiveness of AIxCrypto's strategies to expand its network footprint by 4.36 times since launch. The community surrounding AIxCrypto is vibrant, with over 59,000 members on Discord and strong followings across social media platforms, including 52,000 followers on X and significant engagement on Telegram. This robust community demonstrates not only user participation but also a collaborative spirit, crucial for thriving in the competitive tech landscape.
The launch of Hub S2 marks a strategic milestone, promoting a seamless integration of AI Agent ownership and fostering modular development. Users will have enhanced opportunities to engage with AI Agents, driven by structured prediction competitions designed to encourage innovation and inspire collaboration. With these initiatives, AIxCrypto aims to position itself as a leader in the evolving confluence of AI and blockchain technologies. The focus on creating tools and frameworks for improved product deployment reflects the company's dedication to not just participating in the market but actively shaping the future of AI-driven applications.
In addition to the successful launch of Agentir, AIxCrypto's community-centric approach continues to fuel its expansion. The impressive engagement metrics indicate a high level of user enthusiasm and an inclination toward collaborative development within the ecosystem. The company views user participation as pivotal for shaping the future of AI-driven platforms, ensuring that innovation remains community-focused and aligned with user needs.
Moreover, the emphasis on modularity and natural-language tools signifies a concerted effort to democratize access to AI technology, making advanced AI capabilities accessible to a wider audience. AIxCrypto's ambitious vision caters to both seasoned developers and newcomers to the crypto space, paving the way for a more inclusive future in AI and blockchain integration.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…